KLARIA PHARMA HOLDING AB (6FN)

Overview

Klaria Pharma Holding AB (publ.), based in Uppsala, Sweden, is a noteworthy entity in the pharmaceutical sector, having been established in 2014. It is dedicated to the innovation of medical treatments, with an emphasis on addressing migraines, acute allergic reactions, organ transplant rejection, and the utilization of cannabis/cannabinoids for therapeutic purposes. By venturing into both clinical and pre-clinical phases of product development, Klaria Pharma presents itself as a pivotal player in advancing pharmaceutical solutions, thereby contributing significantly to medical sciences and patient care.

Products and Services

• Sumatriptan

Sumatriptan represents a key development of Klaria Pharma Holding AB for the effective treatment of migraine. With its specific focus on alleviating the symptoms associated with this debilitating condition, Sumatriptan showcases the company's commitment to addressing significant neurovascular disorders.

• Epinephrine/Adrenaline

Currently in Phase I clinical trial, Epinephrine/Adrenaline is being developed for the urgent treatment of acute allergic reactions, commonly known as anaphylaxis. This underscores Klaria Pharma's dedication to crafting lifesaving solutions for critical emergency medical scenarios.

• Sirolimus

In its pre-clinical stage, Sirolimus is aimed at the prevention of organ transplant rejection. This initiative highlights Klaria Pharma's foray into the realm of immunosuppressive treatment, signifying a substantial stride towards enhancing the success rates of organ transplants and patient survival.

• Cannabis/Cannabinoids

Besides its pharmaceutical products, Klaria Pharma is also navigating the research and commercialization paths for cannabis and cannabinoids. With this venture, the company is exploring the potential therapeutic benefits of cannabis derivatives, indicating a broader spectrum of medical applications and patient care possibilities.